Breakthrough Therapies for Metastatic & Primary Cancers

Our multi-patented, ZetaMet™ (Zeta-BC-003) therapy is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone with the potential to increase survival rates.

Latest Updates

Publications & Press Releases

Treating bone metastases with local therapy in a breast cancer patient resulted in decreased pain and prevented fracture

David Palma, Nikhil Thakur, Joe C Loy & Bryan S Margulies.
Here, we report the case of a stage IV breast cancer patient with multiple lytic metastatic lesions to the spine that were successfully treated, which led to a significant reduction in pain and increased quality of life. This outcome demonstrates that a locally administered therapeutic intervention may represent an important alternative for patients with bone metastases that warrants further study.

Zetagen Announces the Appointment of Debasish (Debu) Tripathy M.D. to its Advisory Board

Syracuse, New York, March 18, 2024 – Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company dedicated to developing breakthrough therapies via local administration for the treatment of metastatic and primary cancers in bone and soft tissue organs, today announced the appointment of Debasish (Debu) Tripathy, MD to its advisory board. Dr. Tripathy is Professor and Chairman, Department of Breast Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.

Zetagen Receives Approval in Australia to Begin Pilot Study of ZetaFuse® Bone Graft to Treat Cervical Degenerative Disc Disease

November 6, 2023, (Syracuse, New York) - Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company focused on driving breakthrough innovation in the treatment of metastatic cancers to bone and soft tissue organs as well as osteologic interventions, today announced its approval from the Human Research Ethics Committee (HREC) of Australia to begin a pilot study using its novel therapy ZetaFuse® bone graft for the treatment of cervical degenerative disc disease. The pilot study is a randomized, open-label, two-level cervical program which will examine the safety and efficacy of ZetaFuse® bone graft in patients undergoing anterior cervical discectomy and fusion (ADCF) surgery.
What we do
For Our
Zetagen is focused on the 330,000 people in the United States and more globally, annually living with some form of bone metastases. We have created a series of novel therapies which address metastatic cancers at progressive stages. Our therapies are designed to suspend cancer, inhibit pain, and regenerate bone with the potential of increasing survival rates. These novel drugs from Zetagen are adjunctive to other cancer treatments and can be locally administered, to bone or soft tissue organs, when the lesion is first detected via a brief out-patient procedure. Pre-clinical studies and peer-review published data have shown the potential to reduce lesion size by 200% and in some cases completely resolve, reduce pain by 400+%, and improve mortality rates of 250%.
Discover More
Patients Annually Diagnosed with Breast Cancer
(1 out of 8 Women)
Patients Annually Diagnosed with Metastatic Lytic Bone Lesions
(Breast, Lung, Myeloma, and Prostate)
% of patients Develop Skeletal-Related Event (SRE) from Metastatic Lytic Bone Lesions
*References: Australia ( | Canada ( | USA (,,
Breakthrough Technology

For Metastatic Therapies

The U.S Food and Drug Administration (FDA) has recognized Zetagen’s discoveries with multiple Breakthrough Designations. Zetagen discovered and patented the first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. The small molecule has been approved by the FDA since 1971. Our research scientists have discovered an entirely new pathway for this established molecule which, if proven successful in human clinical trials, could create a new treatment paradigm for patients living with metastatic bone lesions and other osteologic conditions.
Learn More